Esuberaprost
| Esuberaprost.svg | |
Esuberaprost is a synthetic analog of prostacyclin, a potent vasodilator and inhibitor of platelet aggregation. It is primarily used in the treatment of pulmonary arterial hypertension (PAH) and other conditions characterized by poor blood flow.
Pharmacology[edit | edit source]
Esuberaprost acts by mimicking the effects of prostacyclin, a naturally occurring prostaglandin that plays a critical role in vascular homeostasis. Prostacyclin binds to the prostacyclin receptor (IP receptor) on the surface of endothelial cells, leading to increased levels of cyclic adenosine monophosphate (cAMP) within the cell. This results in vasodilation and inhibition of platelet aggregation, which are beneficial in conditions like PAH where blood flow is restricted.
Clinical Use[edit | edit source]
Esuberaprost is administered orally and is used in the management of pulmonary arterial hypertension. It helps to improve exercise capacity and delay clinical worsening in patients with PAH. The drug is often used in combination with other PAH therapies, such as endothelin receptor antagonists and phosphodiesterase-5 inhibitors.
Side Effects[edit | edit source]
Common side effects of esuberaprost include headache, flushing, jaw pain, and gastrointestinal disturbances. These side effects are generally mild and tend to decrease with continued use. However, patients should be monitored for signs of hypotension and bleeding due to the drug's vasodilatory and antiplatelet effects.
Mechanism of Action[edit | edit source]
Esuberaprost exerts its effects by binding to the IP receptor, which is a G protein-coupled receptor. Activation of this receptor leads to the activation of adenylate cyclase, increasing the production of cAMP. Elevated cAMP levels result in the relaxation of vascular smooth muscle cells and inhibition of platelet aggregation.
Research and Development[edit | edit source]
Research into esuberaprost and other prostacyclin analogs continues, with studies focusing on optimizing their efficacy and safety profiles. New formulations and delivery methods are being explored to improve patient compliance and outcomes.
Also see[edit | edit source]
Template:Prostacyclin analogs Template:Pulmonary hypertension treatment
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
